GHK-Cu Side Effects: What Is Documented, What Is Reported, and the Copper Question

The GHK-Cu safety story is usually told in one sentence: it is a naturally occurring human peptide, so it is safe. Half of that is true. GHK is a normal constituent of human plasma, and the cosmetic and wound care use of GHK-Cu goes back decades without a signal of harm. The other half is a leap, because naturally occurring says nothing about injecting milligrams of a copper complex subcutaneously every day, which is a use the human literature has never examined.

This page separates the GHK-Cu side effects that have been documented from those that are only reported, by route, and then works through the one issue that is specific to this compound, the copper. The GHK-Cu guide covers mechanism and evidence, the injection dosage page covers protocols, and the broader class picture is on the peptide side effects page.

What the Human Evidence Actually Covers

There are two controlled human trials of GHK-Cu, and both are topical. Mulder and colleagues ran a multicentre, randomised, evaluator blinded, placebo controlled study of a GHK-Cu gel on diabetic neuropathic foot ulcers, framed explicitly as a safety and effectiveness study (Wound Repair Regen 1994, PMID 17147644). The treated ulcers closed faster and became infected less often, 7 percent against 34 percent for vehicle. The abstract reports no adverse event data one way or the other, which for a daily topical on open wounds in diabetics is a quiet form of reassurance, not proof.

The second is smaller. Miller and colleagues randomised patients to a GHK-Cu skin care regimen or the same regimen without it after CO2 laser resurfacing around the mouth, and in the 13 who completed it blinded evaluators found no difference in erythema resolution and no objective difference in wrinkles or skin quality at 12 weeks, with only patient satisfaction higher in the GHK-Cu group (Arch Facial Plast Surg 2006, PMID 16847171). Its abstract, like Mulder's, reports no adverse event data either way, though a copper peptide product on freshly resurfaced skin is the closer test of topical tolerability for a page like this one.

Beyond that, the topical safety record is the cosmetic industry's. GHK-Cu has been sold in skincare under the INCI name Copper Tripeptide-1 for decades, and the reviews by its discoverer describe controlled studies on aged skin (Pickart, J Biomater Sci Polym Ed 2008, PMID 18644225). Those studies are mostly conference abstracts and company data rather than indexed trials, so the absence of reported harm in them is real but lightly documented.

For GHK-Cu on its own by injection, there is nothing: no human trial, no dose finding study, no pharmacokinetic study. The one published human series of injected GHK-Cu used it as one ingredient of a six component growth factor cocktail injected intradermally into the scalp, open label and uncontrolled, in 1,000 patients (Kapoor and Shome, J Cosmet Laser Ther 2018, PMID 29482481); safety was followed by physical examination, questionnaires and laboratory tests, the treatment was reported as well tolerated, and the paper says nothing about GHK-Cu alone or about subcutaneous systemic use. Every statement about the tolerability of the subcutaneous route, including the ones below, is anecdote or inference from animals. The mouse and rat work is consistent with a benign profile at the doses used, including reduced inflammatory signalling rather than more (Park et al., Oncotarget 2016, PMID 27517151), but animal tolerability is not a human safety study.

Side Effects by Route

The frequency language is deliberately qualitative. Nobody has counted, and a page that gives you percentages for the injected route is inventing them.

The injection sting

GHK-Cu is widely reported to burn on injection, which is not a common complaint with most research peptides, and it is the single most common complaint about this one. There is no published explanation. The plausible candidates, the copper ion, the pH of the reconstituted solution and the concentration, have not been tested against each other. What people do about it is dilute, so the dose sits in a larger volume at a lower concentration, and inject slowly. The dosage page gives the reconstitution table; the 10 mg/mL row is the dilute option.

The blue tint

Copper(II) complexes are blue to violet, GHK-Cu solution is visibly so, and a small volume sitting in subcutaneous fat shows through pale skin for a few hours. It is not a bruise, it is not a reaction, and it disperses as the solution does. It is worth saying once because it alarms people the first time.

Fatigue, headache and mood

A minority of people injecting GHK-Cu report feeling flat, tired or headachy in the first days of a block, and a smaller number report the opposite, a lift in mood. The Bureau's guide mentions both. There is no established mechanism for either and no incidence data. The anti-inflammatory and gene expression effects reported in animals and cells (Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520) make a systemic effect on how someone feels plausible, but plausible is the most that can be said.

Topical irritation and the copper uglies

Some people who start a copper peptide serum report new bumps, congestion or rougher texture over the first weeks, a phenomenon the skincare forums call the copper uglies, and "copper peptides ruined my skin" is a search phrase with real volume. No published study describes it. The candidates are the formulation rather than the peptide, a clash between the copper complex and the vitamin C or acids in the same routine, and simple over use. It typically resolves on stopping, which distinguishes it from an allergy. The topical page covers layering and what to change first.

The Copper Question

This is the only part of GHK-Cu safety that is specific to the molecule, and it is arithmetic rather than opinion. GHK-Cu is about 16 percent copper by mass: the tripeptide weighs roughly 340 daltons, the copper ion roughly 64. A 1 mg injection carries about 0.16 mg of copper, a 2 mg injection about 0.3 mg, and an eight week block at 2 mg daily delivers on the order of 18 mg of copper in total.

On the face of it a 2 mg injection adds a third of a day's dietary copper and about a thirtieth of the upper limit, which is a comfortable margin. Two things narrow it. The dietary figures assume oral intake, where the intestine regulates how much copper is absorbed and the liver disposes of the excess in bile; an injection skips the first step entirely. And the upper limit was set to avoid liver damage from chronic excess, not to describe a level at which nothing else happens. Neither point makes 0.3 mg dangerous. Both are reasons the cycle breaks in circulation are sensible for a compound that has never been studied long term in people.

A separate copper issue is the product itself. GHK binds copper at a defined one to one ratio, and a vendor can sell free GHK with too little copper, or GHK with copper in excess, and label both as GHK-Cu. The peptide fraction shows on an HPLC purity line; the copper content does not, and only a COA that reports it, or elemental analysis, tells you what you have. The testing guide covers how to read one.

Who Should Not Use GHK-Cu

• Anyone with Wilson's disease or another disorder of copper handling. Wilson's disease is a genetic failure to excrete copper, treated with copper chelators and a low copper diet. Adding copper by any route, including topical, works directly against the treatment. This is the one absolute.
• Anyone on a copper chelator such as penicillamine or trientine, for the same reason.
• Pregnancy and breastfeeding. No data by any route. The default for an unstudied compound applies.
• Active cancer or a recent history of it. GHK-Cu increases vascular endothelial growth factor and stimulates angiogenesis and cell migration in wound models (Pickart 2008, PMID 18644225), which are processes a tumour also depends on. Against that, a Connectivity Map analysis predicted that GHK would reverse a metastasis-prone gene signature identified in early stage colorectal cancer, a computational prediction rather than a treatment result (Hong et al., Clin Exp Metastasis 2010, PMID 20143136) and the discoverer's reviews describe anti-cancer actions. Nobody has resolved this in a person. It is a question for the oncologist, not a forum.
• Known copper contact allergy, for the topical route.
• Long injected blocks with no liver monitoring deserve more caution than short ones. Not because harm is expected, but because copper is cleared by the liver and the block is unstudied.

A copper IUD comes up often. There is no data and no mechanistic reason to expect an interaction; the device releases copper locally in the uterus and that is unrelated to a subcutaneous dose. It belongs on the list of things nobody has studied, not the list of things to worry about.

What Is Not a Side Effect

Two things get blamed on GHK-Cu that are not the peptide. The first is the general injection site reaction, redness, a small lump, a bruise, which is technique and site rotation and is covered in the injection guide. The second is contamination or a poorly made product, which the peptide side effects page argues is the largest single variable across the category. A batch of GHK-Cu that is under-coppered does less; a batch with endotoxin does the same thing every contaminated peptide does. Neither is a property of the molecule.

Is GHK-Cu FDA Approved?

No. GHK-Cu has never been approved by the FDA as a drug for any indication, in any form. It is a permitted cosmetic ingredient, listed as Copper Tripeptide-1, and it is sold as a research chemical for laboratory use. The gel used in the 1994 diabetic ulcer trial did not go on to become an approved drug. Research vendors sell GHK-Cu under research use labelling for that reason, and nothing on this page changes that frame. The legal status guide covers what research use labelling means in practice.

Key Takeaways

• Both controlled human trials of GHK-Cu are topical: the diabetic ulcer trial reports fewer infections rather than any harm, and the laser-resurfaced skin trial reports no objective difference from control
• There is no human safety study of GHK-Cu alone by injection; the one injected series was a scalp cocktail, and every statement about subcutaneous tolerability is anecdote or animal inference
• The sting on injection is the most common complaint, has no published cause, and is usually managed by diluting further
• The blue tint at the injection site is the compound's colour
• A 2 mg dose carries about 0.3 mg of copper, a third of the dietary reference intake, delivered without the gut's regulation
• Wilson's disease and copper chelator therapy are the absolute exclusions; cancer history is a clinician question
• The copper content of the product is not on the HPLC purity line; ask for it

For what the compound does and the evidence for it, the complete guide; for the protocols people run, the injection dosage page.

Frequently Asked Questions

What are the side effects of GHK-Cu injections?

The commonly reported ones are a sting or burn at the injection site, a temporary blue tint from the compound's own colour, ordinary injection reactions such as bruising, and in a minority of people fatigue, headache or a change in mood during the first days of a block. None of these has been measured in a trial, because no human trial of GHK-Cu alone by injection exists. The animal work at the doses used shows reduced inflammatory signalling rather than harm, which is reassuring but is not a human safety study.

Is GHK-Cu safe to use long term?

Unknown for the injected route, because it has never been studied long term in people. The topical route has a decades long cosmetic record and two controlled trials, in diabetic ulcers and on laser-resurfaced skin, neither of which reported a safety signal. The specific long term question for injection is copper: a 2 mg daily dose adds about 0.3 mg of copper a day without the intestinal regulation that dietary copper passes through, which is well inside the tolerable upper intake level but is the reason cycle breaks are sensible rather than optional.

Can copper peptides ruin your skin?

Some people report bumps, congestion or rougher texture in the first weeks of a copper peptide serum, which the forums call the copper uglies. No published study describes it, and it usually resolves on stopping, which points to formulation, over use or a clash with vitamin C or acids in the same routine rather than to lasting damage. A true copper contact allergy exists but is rare. Stopping the product is the first step; the formulation is the first suspect.

Who should not use GHK-Cu?

Anyone with Wilson's disease or another copper handling disorder, and anyone on a copper chelator, because the compound delivers copper and works against the treatment. Pregnancy and breastfeeding have no data by any route. Active cancer or a recent history is a conversation for an oncologist, because GHK-Cu stimulates blood vessel growth and cell migration in wound models while a separate computational analysis predicted it would reverse a metastasis-prone gene signature in colorectal cancer, and no one has resolved that in a person.

Is GHK-Cu FDA approved?

No. It has never been approved by the FDA as a drug for any indication or in any form. It is a permitted cosmetic ingredient under the name Copper Tripeptide-1, and it is sold for laboratory research under research use labelling. The gel used in the 1994 diabetic ulcer trial did not go on to become an approved drug.